Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $463K | $318K | $50.1M | $45.6M | $134M | $176M | $235M | $283M |
| Revenue growth | — | -31.3% | 15660.4% | -9.0% | 193.9% | 31.0% | 34.0% | 20.4% |
| Operating income | -$55.2M | -$90.9M | -$104M | -$181M | -$111M | -$91.7M | -$4.69M | $105M |
| Operating margin | -11930.9% | -28598.4% | -208.1% | -396.3% | -83.2% | -52.2% | -2.0% | 37.1% |
| Net income | -$53.1M | -$88.4M | -$103M | -$181M | -$108M | -$78.0M | $5.75M | $287M |
| Net margin | -11464.1% | -27794.0% | -204.9% | -396.8% | -80.7% | -44.5% | 2.4% | 101.5% |
| EPS (diluted) | -$0.63 | -$0.95 | -$0.87 | -$1.40 | -$0.76 | -$0.54 | $0.04 | $2.07 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$51.6M | -$63.6M | -$69.9M | -$158M | -$79.5M | -$33.5M | $44.4M | $136M |
| Share buybacks | — | — | — | — | $0.00 | $0.00 | $40.2M | $98.2M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $118M | $306M | $272M | $232M | $94.1M | $48.8M | $83.4M | $80.2M |
| Total assets | — | $324M | $464M | $543M | $471M | $548M | $551M | $752M |
| Total liabilities | — | $25.7M | $55.9M | $64.3M | $65.4M | $170M | $173M | $170M |
| Shareholders' equity | $136M | $299M | $408M | $479M | $405M | $378M | $377M | $581M |
| Retained earnings | — | -$472M | -$575M | -$756M | -$864M | -$942M | -$937M | -$649M |
| Shares (wtd avg diluted) | 85.5M | 112M | 118M | 129M | 142M | 143M | 146M | 139M |
Every figure is extracted from Aurinia Pharmaceuticals Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.